Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Income (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Net Income for 7 consecutive years, with -$194.6 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 27.21% to -$194.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$704.5 million through Dec 2025, down 33.87% year-over-year, with the annual reading at -$732.9 million for FY2025, 34.89% down from the prior year.
  • Net Income hit -$194.6 million in Q4 2025 for BridgeBio Pharma, down from -$185.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$19.1 million in Q1 2024 to a low of -$267.4 million in Q4 2024.
  • Historically, Net Income has averaged -$155.4 million across 5 years, with a median of -$163.2 million in 2023.
  • Biggest five-year swings in Net Income: surged 86.59% in 2024 and later tumbled 640.71% in 2025.
  • Year by year, Net Income stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then crashed by 39.19% to -$267.4 million in 2024, then increased by 27.21% to -$194.6 million in 2025.
  • Business Quant data shows Net Income for BBIO at -$194.6 million in Q4 2025, -$185.0 million in Q3 2025, and -$183.8 million in Q2 2025.